Key facts
- It has raised $87.5M; the latest was Early Stage VC ($40.0M) in Apr 2025.
- Notable investors include Qiming Venture Partners, GL Ventures, Shunwei Capital, 5Y Capital, K2VC — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for LTZ Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for LTZ Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LTZ Therapeutics
Developer of novel immunotherapies designed to treat patients suffering from cancer and other diseases. The company utilizes reverse translational science and tumor biology combined with machine learning to develop immunotherapy, enabling patients to access novel cancer treatment.
- Sector
- Healthcare
- HQ
- Redwood City, CA, United States
- Founded
- 2022
- Employees
- 36
- Website
- ltztherapeutics.com/
- Ownership
- Privately Held (backing)
LTZ Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LTZ Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LTZ Therapeutics in its N-PORT filings yet. We sweep new filings monthly.